Artificial Intelligence in Drug Discovery

Artificial Intelligence in Drug Discovery encompasses machine learning, deep learning, and other computational intelligence approaches analysing large datasets to identify patterns enabling prediction of molecular properties, target interactions, biological activities, and clinical outcomes, accelerating pharmaceutical development through data-driven hypothesis generation and prioritisation.

The biopharmaceutical industry has rapidly adopted artificial intelligence across drug discovery workflows. Generative AI designs novel molecular structures with predicted target activity and drug-like properties. Graph neural networks predict molecular properties from chemical structure graphs. Deep learning models analyse protein structures predicting binding sites and drug interactions. Natural language processing mines scientific literature identifying novel targets and mechanisms. Clinical trial data analysis identifies biomarker signatures predicting patient responses. Manufacturing process optimisation employs machine learning identifying relationships between process parameters and product quality. As datasets grow, algorithms improve, and computational infrastructure scales, artificial intelligence continues transforming pharmaceutical development through accelerated target identification, lead optimisation, clinical development, and manufacturing.